SCHEMBL4256822

SCHEMBL4256822

Cc1oc(-c2ccc(NC(=O)c3ccc(Cl)cc3Cl)cc2)nc1-c1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMO Q99835 6/20 0.80
MAPT P10636 5/20 0.57
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
CYP2C19 P33261 1/20 0.53
KDM4E B2RXH2 4/20 0.52
POLB P06746 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
GAA P10253 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
GPR27 Q9NS67 3/20 0.49
AVPR2 P30518 2/20 0.49
JAK2 O60674 1/20 0.49
JAK1 P23458 1/20 0.49
TYK2 P29597 1/20 0.49
HTT P42858 1/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12847978 0.92 SMO (0.80) SMOMAPTMEN1KMT2AKDM4E
SCHEMBL4262829 0.89 SMO (1.00) SMOMAPTMEN1KMT2ACYP2C19
SCHEMBL4266575 0.89 SMO (1.00) SMOMAPTMEN1KMT2ACYP2C19
SCHEMBL4257574 0.85 SMO (0.81) SMOMAPTMEN1KMT2ACYP2C19
SCHEMBL14148825 0.82 KDR (0.54) SMOMAPTMEN1KMT2ACYP2C19
SCHEMBL4254933 0.80 SMO (0.79) SMOMAPTMEN1KMT2ACYP2C19
SCHEMBL13576589 0.80 MAPT (0.71) MAPTMEN1KMT2ACYP2C19KDM4E
SCHEMBL4262062 0.77 SMO (0.69) SMOMAPTMEN1KMT2ACYP2C19
SCHEMBL4261338 0.76 SMO (0.80) SMOMAPTMEN1KMT2ACYP2C19
SCHEMBL4257675 0.76 SMO (0.74) SMOMAPTCYP2C19KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US claimed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US claimed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO claimed
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US disclosed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US disclosed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE OXA1L, CYP11B2, CYP3A7 SMO 1063/4885MAPT 2622/4885MEN1 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.